Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma

The objective of this study is to evaluate the efficacy and safety profiles of the targeted medications, bevacizumab and cetuximab, in combination with cytostatic drugs in patients with locally advanced or metastatic pancreatic cancer. In this retrospective phase 2 study, a total of 59 patients with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Medicine (Baltimore)
Glavni autori: Tai, Cheng-Jeng, Huang, Ming-Te, Wu, Chih-Hsiung, Wang, Chien-Kai, Tai, Chen-Jei, Chang, Chun-Chao, Hsieh, Cheng-I., Chang, Yu-Jia, Wu, Chang-Jer, Kuo, Li-Jen, Wei, Po-Lei, Chen, Ray-Jade, Chiou, Hung-Yi
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2016
Teme:
5700
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839806/
https://ncbi.nlm.nih.gov/pubmed/27082562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003259
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items